Popular topics to explore
trading near its 52 week breakout level.
trading near its 52 week breakout level. !PPLPHARMA is trading near its 52 week breakout level. • The 52-week breakout strategy focuses on stocks that cross their highest price of the past one year, often indicating strong bullish momen…
PIRAMAL PHARMA BUYS MAJORITY STAKE IN YAPAN BIO
PPLPHARMA has acquired over 40% stake in contract development and manufacturing organisation (CDMO) Yapan Bio for Rs 76 crore. With the completion of the transaction, Piramal has become the majority shareholder with 74 per recent stake an…
Piramal Pharma Acquires 40.67% Stake In Yapan Bio For ₹76 Crore, Making It Subsidiary
PPLPHARMA has increased its equity stake in Yapan Bio to 74.00% from 33.33% for ₹76 crore, utilizing a call option to elevate Yapan Bio's status from an associate company to a subsidiary. This acquisition integrates Yapan's process develop…
WATCH OUT FOR STOCKS IN NEWS
Watch out for the below mentioned stocks in news which are likely to be on spotlight for today the 14-Aug-2026 : - Piramal Pharma: An existing shareholder is likely to sell a 6 per cent stake in Piramal Pharma through block deals, with the…
TEXRAIL
**Strategic MoU & Shareholding Update**
** TEXRAIL :** Signed an **MoU with Skoda Digital S.R.O. (Czech Republic)** to explore opportunities in **railway digitalization, signalling and smart mobility solutions**.
**Impact:** **Positive;*…
PPLPHARMA : CO RESUMES OPERATIONS AT AHMEDABAD FACILITIES FOLLOWING FLOOD DISRUPTION
PIRAMAL PHARMA: CO RESUMES OPERATIONS AT AHMEDABAD FACILITIES FOLLOWING FLOOD DISRUPTION
WATCH OUT FOR STOCKS IN NEWS
Watch out for the below mentioned stocks in news which are likely to be on spotlight for today the 30-Jul-2026 : - The stocks of UltraTech Cement, Dr. Lal PathLabs, BASF India & Cheviot Company will trade Ex-Dividend today. Eicher Motors:…
29th Jul · SEBI Registration INH000016074
SEBI Registration INH000016074 · 29th Jul
Piramal Pharma Q1: Loss Narrows, Margins Improve
📌 Piramal Pharma Q1 FY26 Results Net Loss: ₹694M vs ₹817M (YoY) ⬇️ Revenue: ₹22.7B vs ₹19.33B (YoY) ⬆️ EBITDA: ₹1.95B vs ₹1.07B (YoY) ⬆️ EBITDA Margin: 8.6% vs 5.5% (YoY) ⬆️ 📊 Fundamentals & Ratios Revenue: ~₹85B Net Loss: ~₹3.2B…
29th Jul · SEBI Registration INH000016074
SEBI Registration INH000016074 · 29th Jul
Market Opening Snapshot
📊 Market Opening Snapshot GIFT Nifty: 24,221 (+130 pts) → gap-up start. Sensex (Prev Close): 76,766 (–0.09%). Nifty 50 (Prev Close): 23,985 (–0.04%). Bank Nifty (Prev Close): 56,756 (–0.58%). 🌍 Global Market & Commodities US Markets: Dow…
PPLPHARMA
Piramal Finance reported a strong performance for the first quarter of FY27, with consolidated net profit rising 66.8% year-on-year to Rs 460.98 crore, compared with Rs 276.37 crore in the corresponding quarter last year. The growth was dri…
Piramal Pharma Gains 3% After FDA Closes Inspection
Piramal Pharma shares rose 3.3% to ₹173.59 after the US FDA issued an Establishment Inspection Report for its Sellersville, Pennsylvania facility successfully closing the inspection that began in May 2026. A clean EIR removes a major regula…
27th Jun · SEBI Registration INH000020350
SEBI Registration INH000020350 · 27th Jun
Technical Analysis Piramal Pharma Limited.
The stock PPLPHARMA is after a prolonged downtrend the stock found a very strong bottom support level around the 130-140 zone earlier in the year. From that bottom it made a solid recovery pushing up to create a short-term uptrend that pea…
Market Momentum
Market action today is supported by strong momentum across select mid-cap and specialty names, driven by a mix of corporate developments, strategic expansion, and improving earnings visibility. Stocks such as Piramal Pharma are witnessing t…
19th Jun · SEBI Registration INH000018142
SEBI Registration INH000018142 · 19th Jun
India's pharmaceutical industry has experienced considerable change in the last 12 years, improving healthcare access, encouraging low-cost medications, and boosting independence in drug manufacturing. The Government reports that India has…
PPLPHARMA
### PPLPHARMA | Strong FY26 Performance, Confident FY27 Outlook
Piramal Finance reported a **210% YoY jump in FY26 consolidated net profit to ₹1,506 crore**, driven by strong retail lending growth and improving asset quality.
**Net In…
29th Apr · SEBI Registration INH000015376
SEBI Registration INH000015376 · 29th Apr
Piramal Pharma posts Rs 8.82 crore consolidated net loss in Q4FY-26
The company has reported 5.64% fall in its net profit at Rs 261.63 crore for fourth quarter ended March 31, 2026 (Q4FY26) as compared to Rs 277.27 crore for the same quarter in the previous year. Total income of the company decreased by 3.2…
PPLPHARMA
Piramal Finance shares surged sharply today, climbing nearly 12% in midday trading to ₹2,062 after the company posted a strong performance for the March quarter and shared an optimistic growth outlook. Over the past year, the stock has rall…
26th Apr · SEBI Registration INH000016649
SEBI Registration INH000016649 · 26th Apr
Market Divergence Deepens: Smallcaps Take the Lead
While headline indices remained under pressure, the real traction was visible in the broader market. Select smallcap stocks delivered strong, confidence-boosting rallies, highlighting underlying strength despite volatility in largecaps. Le…
Piramal Pharma Building Scale Across CDMO and Complex Generics
PPLPHARMA Piramal Pharma continues to expand its presence across contract development and manufacturing (CDMO), complex hospital generics, and consumer healthcare segments. Its diversified business model and global client base provide resi…
Piramal Pharma Gets VAI Status from US FDA
🧪 PPLPHARMA has successfully completed a US FDA inspection at its Lexington facility, receiving a Voluntary Action Indicated (VAI) status, indicating satisfactory compliance with regulatory standards.
